DSMM XIX

A randomized phase III non-inferiority trial assessing lenalidomide, bortezomib and dexamethasone induction therapy with either intravenous or subcutaneous isatuximab in transplant-eligible patients with newly diagnosed multiple myeloma

2022-000996-38

EMN30
MajesTEC-4

Teclistamab + Lenalidomide and Teclistamab Mono versus Lenalidomide Mono in NDMM as Maintenance Therapy Following Autologous Stem Cell Transplantation

Eudract Nr. 2021-002531-27

DSMM XVIII
GMMG-HD9

Randomisierte Phase 3-Studie zur Untersuchung einer Erhaltungstherapie mit Iberdomid versus Iberdomid plus Isatuximab nach autologer hämatopoetischer Blutstammzelltrans-plantation für Patienten mit neudiagnostiziertem Multiplem Myelom

Eudract Nr. 2023-507402-13-00

IM048-022

A Phase 3, Two-stage, Randomized, Multi-center, Controlled, Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Therapy After Autologous Stem Cell Transplantation (ASCT) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) (EXCALIBER-Maintenance)

2022-501515-14-00

CA057-008
Successor-2

A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma

NCT05552976